Drilldown: Medicines

None (2) · Codeine (2)

Other values:

Search

None (30) · (multiple, generic dominant) (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Dolophine (1) · Duragesic (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Nubain (1) · Nucynta (1) · Opana (1) · Stadol (1) · Suboxone (1) · Sunosi (1) · Talwin (1) · Vicodin (1) · Wakix (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antipsychotic · Antiparkinsonian · Empathogen · Neuroleptic · Cathinone

Other values:

Search

None (1) · 5-HT2A agonist (12) · 5-HT2A agonist; long duration (1) · 5-HT2A agonist; MAO inhibitor (1) · 5-HT2A agonist; milder than other 2C-x (1) · 5-HT2A partial agonist (1) · Extremely potent 5-HT2A agonist; vasoconstrictor (1) · Extremely potent 5-HT2A agonist; very long duration (1) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; NMDA antagonist (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Partial mu-opioid agonist; kappa antagonist (1) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent 5-HT2A agonist (5) · Potent 5-HT2A agonist; no oral activity (1) · Potent 5-HT2A agonist; very long duration (1) · Potent mu-opioid receptor agonist (3) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Selective dopamine and norepinephrine reuptake inhibitor (DAT and NET inhibition). Unlike amphetamine, does not significantly release monoamines, pure reuptake inhibition. (1) · Very potent 5-HT2A agonist; long duration (1)

None (43) · Excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea (OSA) (1) · Excessive daytime sleepiness or cataplexy in adults with narcolepsy (FDA-approved August 2019) (1) · Mild to moderate pain; cough suppression (low-dose). (1)

None (43) · Adult: 15–60 mg every 4 hours as needed. (1) · Narcolepsy: 75 mg PO once daily upon awakening, titrate every 3 days. OSA: 37.5 mg PO once daily, titrate. (1) · Week 1: 8.9 mg PO once daily in the morning. Week 2: 17.8 mg. Week 3+: 35.6 mg (max). Titrate as needed. (1)

None (43) · 4.45 mg, 17.8 mg tablets (1) · 75 mg, 150 mg tablets (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (43) · 150 mg/d (1) · 35.6 mg/d (1) · 360 mg/day (1)

None (42) · insufflated (1) · Oral (3) · PO (only formulation marketed in the US). (1) · PR (1)

None (42) · 30–60 min (PO) (1) · 45-75 min (oral) (1) · Wake-promoting effect over weeks of titration (1) · ~30-60 min (1)

None (42) · 4-8 h (1) · 4–6 hours (1) · Daily morning dosing (1) · ~9 hours (1)

None (42) · 2.5–3 hours (1) · Not well characterized (1) · ~20 hours (1) · ~7.1 hours (1)

None (42) · Not formally established; oral once-daily adequate (1) · Not well characterized (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~95% (1)

None (42) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Limited data; pitolisant may reduce hormonal contraceptive efficacy (1) · Limited data; pregnancy exposure registry available (1) · Not established (1)

None (42) · Rx, '''not a controlled substance''' (unique among wake-promoting agents) (1) · Rx, Schedule IV (US) (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)